Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults

Learn more about:
Related Clinical Trial
Safety and Efficacy of Injectable Poly-L-Lactic Acid for Volume Loss in the Temples Using Dual Plane Injections Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan’s Lipodystrophy Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy Intraoperative Fluid Management of Liposuction , Cardiometry Versus Rohrich Formula The Visceral Adiposity Measurement and Observation Study Evaluating the Performance and Safety of the Medical Device Plenhyage® in the Treatment of Dermal Tissue Defects Evaluating the Performance and Safety of the Medical Device Auralya® in the Treatment of Facial Dermal Tissue Defects Evaluating the Performance and Safety of the Medical Device Janesse in the Treatment of Facial Dermal Tissue Defects Evaluating Performance and Safety of the Medical Device Jalucomplex in the Treatment of Facial and Neck Tissue Defects Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH. Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome Exercise and Pioglitazone for HIV-Metabolic Syndromes Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults Yoga for the Management of HIV-Metabolic Syndromes Pravastatin for Hyperlipidaemia in HIV. A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth Exercise for Patients With HIV Infections Lactate Metabolism Study in HIV Infected Persons Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells Growth Hormone Dynamics and Cardiac Steatosis in HIV The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers Detraining in People Living With HIV/AIDS SHARE: Simple HAART With Abacavir, Reyataz, and Epivir The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Metabolism and Body Shape of Healthy Children and Children With Chronic Infections Changing to Nonprotease Inhibitor Treatment to Improve Side Effects Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs White Light Scanning to Aid Body Contouring: A Pilot Project Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy The Cleveland Cardiometabolic Cohort Metabolic Abnormalities in HIV-infected Persons Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients. Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome Effects of Short-term Growth Hormone in HIV-infected Patients Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid Raltegravir Therapy for Women With HIV and Fat Accumulation The PREFORM Study: A Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring Effects of IGF-I in HIV Metabolic Disease Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy Effects of Growth Hormone Releasing Hormone in HIV A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy Body Composition and Adipose Tissue in HIV Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue CONFORM: Rotational Fractional Resection for Submental Contouring Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy TH9507 in Patients With HIV-Associated Lipodystrophy TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Energy Expenditure of People Living With HIV/AIDS Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Egrifta Replacement and Sleep Disordered Breathing Clinical Trial to Determine the Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients Low Energy Diet and Familial Partial Lipodystrophy Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Role of the Autonomic Nervous System in HIV-Lipodystrophy Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome Therapeutic Approaches to HAART-Induced Lipodystrophy Different Surgical Modalities for Thigh Lipodystrophy Including Liposuction,Thigh Lift and Liposuction Assisted Thigh Lift Leptin to Treat Lipodystrophy Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat Corticosteroid-induced Lipodystrophy and Adipokines Short-term Effects of Leptin in People With Lipodystrophy Leptin to Treat Lipodystrophy Lipodystrophy Connect Patient Registry An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy

Brief Title

Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults

Official Title

Fat Redistribution and Metabolic Change in HIV Infection (FRAM)

Brief Summary

      The purpose of this study is to collect data on the body's breakdown of sugar and fat in HIV
      infected adults. Data from this study will make clearer the roles of HIV infection and
      anti-HIV drugs in the development of diabetes, heart disease, and fat redistribution in HIV
      infected adults.

Detailed Description

      Changes in the amount of fat and how that fat was distributed were reported after the
      introduction of antiretroviral therapy (ART) for HIV infected patients. Increases in
      diabetes, heart disease, and blood levels of glucose and fats have also been reported.
      However, the cause for these changes is still unclear, in part because clinical measures have
      not been consistent between different trials. The contribution of age, duration of HIV
      infection, duration and types of ART, and body weight on metabolic changes need to be
      defined, and the relationship between metabolic disturbances and body composition changes has
      also not been established. The purpose of this study is to examine HIV infected adults and
      use objective measurements of fat to determine metabolic changes in this population, their
      causes, and possible associations with other observed changes. Data from this study will help
      guide future treatment plans for HIV infected people to help prevent or lessen the risk for
      diabetes and cardiovascular disease.

      There are 2 parts to this study. Part 1 will examine fat redistribution; there will be 2
      groups in Part 1. Group 1 participants will be HIV infected adults recruited from specific
      HIV clinics. Group 2 participants will be HIV uninfected adults currently enrolled in the
      Coronary Artery Risk Development in Young Adults (CARDIA) study. Participants will undergo
      hands-over-head-to-toe wide-slice magnetic resonance imaging (MRI) and dual energy x-ray
      absorptiometry (DEXA). Imaging measurements will be compared to anthropometric measurements
      to determine whether anthropometric measurements can accurately quantify fat redistribution.
      Participants will be asked to self-report fat distribution abnormalities, and this
      self-reporting will be evaluated for accuracy as compared to the quantitative measures of
      regional fat distribution. Blood collection will also occur to determine the possible
      association of body composition changes with the types of ART a participant may have taken or
      currently be taking.

      Part 2 of this study will examine cardiovascular disease and factors for its development;
      there will be 2 groups in Part 2. Group 1 participants will be HIV infected adults recruited
      from specific HIV clinics. Group 2 participants will be HIV uninfected adults currently
      enrolled in the CARDIA study. All participants will be assessed for blood pressure, family
      history, lifestyle habits, and regional fat volumes by MRI and DEXA. Blood collection will
      occur to test for glucose and lipids (traditional metabolic risk factors) and C-reactive
      protein (CRP) and cytokines (novel inflammatory risk factors). Participants will also undergo
      a carotid intimal medial thickness (IMT) measurement by ultrasound to determine the
      prevalence of atherosclerosis in this population and associated contributing factors.

      For Part 2, there will be a minimum of 2 visits. At both visits, fasting blood collection
      will occur. A physical exam and self-reporting of lifestyle habits, and completion of
      questionnaires about smoking, alcohol use, and medical and family history will occur at the
      first visit.

Study Type



HIV Infections


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

June 2000

Completion Date

July 2007

Eligibility Criteria

        Inclusion Criteria for Group 1 in Parts 1 and 2:

          -  HIV infected

          -  Recruited from an HIV clinic participating in this study

        Inclusion Criteria for Group 2 in Parts 1 and 2:

          -  HIV uninfected

          -  Participating in the CARDIA study

        Exclusion Criteria:

          -  Inability to undergo DEXA and MRI studies




18 Years - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers


Carl Grunfeld, MD, PhD, , 

Administrative Informations



Organization ID

DK-57508 / HL-74814

Secondary IDs


Study Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)


 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Study Sponsor

Carl Grunfeld, MD, PhD, Principal Investigator, Northern California Institute for Research and Education, University of California, San Francisco, Veterans Affairs Medical Center

Verification Date

May 2006